Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of the Safety, Tolerability, and Efficacy of Parsaclisib in Combination With Ruxolitinib in Subjects With Myelofibrosis

Next Previous
X
Search
Trial Profile

A Phase 2 Study of the Safety, Tolerability, and Efficacy of Parsaclisib in Combination With Ruxolitinib in Subjects With Myelofibrosis

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 May 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Parsaclisib (Primary) ; Ruxolitinib (Primary)
  • Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Incyte Corporation

    • Most Recent Events

    • 02 Apr 2024 Status changed from completed to discontinued.
    • 13 Dec 2022 Final Results From a Phase 2 Study assessing efficacy and safety results from the completed study presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 10 Dec 2022 According to an Incyte media release, data from this study were presented at the 64th American Society of Hematology (ASH) Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top